Botulinum toxin A in the treatment of blepharospasm: a 10-year experience

Silveira‐Moriyama, Laura; Gonçalves, Lílian Regina; Chien, Hsin Fen; Barbosa, Egberto Reis

doi:10.1590/s0004-282x2005000200006

Cited by 23 publications

(24 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ptosis was the most frequent adverse effect in both groups, which was less common in the pretarsal injection group compared with the preseptal injection group. Our findings in HFS and BPS are consistent with those in earlier studies (18,19,20,21). CD is the most common form of adult-onset focal dystonia.…”

Section: Discussionsupporting

confidence: 93%

“…BoNT is currently the most common treatment modality in BPS (12). Silveira-Moriyama et al (18) analyzed a total of 379 treatments with BoNT type A in 30 patients with BPS. They reported that the mean duration of improvement was 2.64 months, 93% of the patients exhibited considerable improvement after the first BoNT injection, and adverse effects, which were commonly minor, developed at least once in 53% of patients in their study.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Applications of Botulinum Toxin at a Neurology Clinic: An Eleven-year Experience

Koyuncuoğlu¹,

Demirci²

2016

tnd

View full text Add to dashboard Cite

Objective: The aim of this study was to report our experience with Botulinum toxin (BoNT) in the treatment of various neurologic conditions. Materials and Methods:We conducted a retrospective analysis of 128 patients who received BoNT in our Neurology clinic during an 11-year period (January 2003 to December 2014). All patients received BoNT type A injections.Results: A total of 858 injections of BoNT were administered to 128 patients. Seventy (54.7%) patients with hemifacial spasm had 456 injection sessions, 24 (18.8%) patients with blepharospasm had 209 injection sessions, 21 (16.4%) patients with cervical dystonia had 145 injection sessions, 8 (6.3%) patients with spasticity had 29 injection sessions, 3 (2.3%) patients with migraine-type headache had 14 injection sessions, 1 (0.8%) patient with sialorrhea had 3 injection sessions, and 1 (0.8%) patient with upper-extremity dystonia underwent 2 injection sessions. The mean onset of effects after injection was 7.11±2.34 days, the duration of effect was 13.0±5.46 weeks, and the amount of improvement was 61.5±16.7% in all patients. A total of 27 (3.14%) adverse effects were recorded in 858 injection sessions. The adverse effects were mild and tolerable. Conclusion:Our results show that BoNT type A is an effective and safe therapy for various types of neurologic conditions. Keywords: Botulinum toxin, efficacy, safetyAmaç: Çalışmanın amacı çeşitli nörolojik hastalıkların tedavisinde kullanılan Botulinum toksini (BoNT) ile olan deneyimlerimizi bildirmektir. Sonuç: Sonuçlarımız BoNT tip A tedavisinin birçok nörolojik hastalıkta etkili ve güvenli bir tedavi yöntemi olduğunu göstermektedir. Gereç ve

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Applications of Botulinum Toxin at a Neurology Clinic: An Eleven-year Experience

Koyuncuoğlu¹,

Demirci²

2016

tnd

View full text Add to dashboard Cite

show abstract

“…In a previous Brazilian study, 30 patients with BPS under BTX-A treatment were evaluated and about 93% of them had symptom improvement, with maintenance of relief duration in the time of follow up and low incidence of side effect 18 . On Figure. Severity of blepharospasm before and after first botulinum toxin injection.…”

Section: Therapeutic Outcomesmentioning

confidence: 99%

Clinical features and treatment with botulinum toxin in blepharospasm: a 17-year experience

Aquino

Felı́cio

Castro

et al. 2012

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

OBJECTIVE: It was to analyze clinical aspects of patients with blepharospasm, including outcomes of botulinum toxin treatment. Additionally, clinical characteristics of isolated blepharospasm were compared to those of blepharospasm plus other movement disorders. METHODS: Clinical data recorded during 17 years were reviewed. The variables included age, gender, age of onset, past medical history, head trauma, smoking history, family history of dystonia, severity, duration of botulinum toxin relief and adverse effects. RESULTS: A total of 125 patients were included and 75.2% were female. The mean age of onset was 54.3 years; 89.6% of the individuals started with contractions in eye region, and 39.2% of them spread to lower face or neck. Isolated blepharospasm group was compared with blepharospasm-plus group for demographic and clinical features, and therapeutic outcomes, without significant differences. Botulinum toxin treatment improved the severity of contractions (p=0.01) with low rate of side effects (14%). CONCLUSIONS: Both groups - isolated blepharospasm and blepharospasm-plus - shared similar results concerning epidemiology, clinical features and therapeutic response to botulinum toxin.

show abstract

“…[4][5][6][7][8][9][10][11][12][13] Although many patients experience rapid symptomatic relief, the effects of botulinum toxin are temporary, and many patients develop resistance to its effects with repeated injections. Thus, there are patients whose symptoms are poorly controlled with botulinum toxin injections alone.…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3] The first-line treatment for this condition is serial botulinum A toxin injections, which are effective for the rapid but temporary treatment of BEB. [4][5][6][7][8][9][10][11][12][13] In patients who fail to respond to this treatment, protractor myectomy, which has been performed routinely for decades, remains a highly effective treatment, with few complications. [14][15][16][17][18][19][20][21][22][23] Nevertheless, postoperative complications can arise, including hemorrhage, hematoma, lid edema, lagophthalmos, skin necrosis, and skin contracture.…”

Section: Introductionmentioning

confidence: 99%

Surgical approach to limiting skin contracture following protractor myectomy for essential blepharospasm

Clark

Randolph

et al. 2017

Digit J Ophthalmol

View full text Add to dashboard Cite

Purpose-To report our experience with protractor myectomy in patients with benign essential blepharospasm who did not respond to serial botulinum toxin injection, and to describe intra-and postoperative techniques that limited skin contracture while also providing excellent functional and cosmetic results.Methods-The medical records of patients with isolated, benign, essential blepharospasm who underwent protractor myectomy from 2005 to 2008 by a single surgeon were reviewed retrospectively. The technique entailed operating on a single eyelid during each procedure, using a complete en bloc resection of all orbicularis tissue, leaving all eyelid skin intact at the time of surgery, and placing the lid under stretch with Frost suture and applying a pressure dressing for 5-7 days.Results-Data from 28 eyelids in 7 patients were included. Average follow-up was 21.5 months (range, 4-76 months). Of the 28 eyelids, 20 (71.4%) showed postoperative resolution of spasm, with no further need for botulinum toxin injections. In the 8 eyelids requiring further injections, the average time to injection after surgery was 194 days (range, 78-323 days), and the average number of injections was 12 (range, 2-23 injections). All but one eyelid had excellent cosmetic results, without signs of contracture; one eyelid developed postoperative skin contracture following premature removal of the Frost suture and pressure dressing because of concerns over increased intraocular pressure.Conclusions-In our patient cohort, this modified technique resulted in excellent cosmetic and functional results and limited postoperative skin contracture.

show abstract

Botulinum toxin A in the treatment of blepharospasm: a 10-year experience

Cited by 23 publications

References 12 publications

Applications of Botulinum Toxin at a Neurology Clinic: An Eleven-year Experience

Applications of Botulinum Toxin at a Neurology Clinic: An Eleven-year Experience

Clinical features and treatment with botulinum toxin in blepharospasm: a 17-year experience

Surgical approach to limiting skin contracture following protractor myectomy for essential blepharospasm

Contact Info

Product

Resources

About